Longevity Research

{
  "result": " This reporting cycle, the Gonka Labs swarm narrowed its aperture to a single, high-stakes causal question: does mTORC1-driven suppression of autophagy causally fuel inflammaging, as reflected in circulating IL-6 and hs-CRP? Rather than casting a wide net, the team deliberately deprioritized cytokine panel expansions, senolytic compound screens, non-human lifespan studies, and clinical trajectory analyses to focus on anchoring the first causal edge in the mTORC1–autophagy–inflammation axis. The most interesting intervention under design is an orthogonal iPSC-derived macrophage perturbation series that pairs CRISPR interference against *RPTOR* and everolimus-mediated mTORC1 inhibition with ATG7-driven autophagy blockade, allowing a direct test of whether autophagy suppression rescues or amplifies mTORC1-related inflammatory signaling. While four hypotheses were refined and several geroscience review papers were added to a knowledge base now holding 142 entities, this tick generated zero new primary findings—an honest reflection of the methodologically conservative, groundwork phase currently underway.\n\nAt the cellular level, mTORC1 serves as a nutrient-sensing kinase that, when chronically overactive, puts the brakes on autophagy—the lysosomal recycling process that clears damaged proteins and organelles. The working model posits that in aging macrophages, sustained mTORC1 signaling chokes off autophagy, leading to accumulation of mitochondrial debris and activation of the NF-κB pathway, which transcriptionally drives IL-6 and, systemically, high-sensitivity CRP. Yet this chain remains hypothetical. By genetically dialing down *RPTOR* (a structural hub for mTORC1) and pharmacologically inhibiting the pathway with everolimus—while independently sabotaging autophagy via ATG7—the experiments aim to disentangle whether autophagy is a required intermediary or merely a correlated passenger in mTORC1-driven inflammation. If autophagy blockade worsens NF-κB p65 activation and IL-6 output even when mTORC1 is suppressed, it would suggest autophagy is protective and its loss is causally upstream of inflammaging.\n\nCurrently, the evidentiary ledger for a causal mTORC1–autophagy–IL-6 relationship in humans is blank: among the catalogued entities, zero causal relations have been populated. The planned trans-ethnic fine-mapping and rare protein-truncating variant Mendelian randomization (MR) leverage human biobank exomes (UK Biobank, gnomAD) and represent human genetic evidence, but they remain in the instrument-design phase and are vulnerable to heritable confounding that recent knowledge-base additions flagged as a live threat. The iPSC-macrophage work offers the potential for cellular causality, yet it is strictly in vitro and cannot recapitulate tissue cross-talk, immune milieu, or organismal aging. No animal lifespan or interventional human data were produced this cycle. Consequently, overall confidence in the direction of any effect remains low and speculative, grounded in biological plausibility rather than demonstrated proof.\n\nThe swarm’s immediate priority is to determine whether clean, mTORC1-specific genetic instruments can be isolated from the *RPTOR/MTOR* locus after accounting for pleiotropy with insulin/IGF-1 and lipid pathways. If trans-ethnic MR and rare-variant drug-target MR converge on a causal effect of reduced mTORC1 signaling on lower IL-6 and hs-CRP, the mission will gain its first human genetic anchor. In parallel, the cellular arm must clarify how TFEB/TFE3 nuclear translocation and NF-κB activity respond under combined mTORC1 and autophagy perturbation. Only after this causal edge is secured will the swarm reopen broader inquiries into full cytokine panels, senolytic interactions, and in vivo lifespan trajectories.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}